TY - JOUR
T1 - Pulmonary oligometastases treated by stereotactic body radiation therapy
T2 - A nationwide survey of 1,378 patients
AU - Niibe, Yuzuru
AU - Yamamoto, Takaya
AU - Onishi, Hiroshi
AU - Yamashita, Hideomi
AU - Katsui, Kuniaki
AU - Matsumoto, Yasuo
AU - Oh, Ryoong Jin
AU - Aoki, Masahiko
AU - Shintani, Takashi
AU - Yamada, Kazunari
AU - Kobayashi, Mitsuru
AU - Ozaki, Masatoki
AU - Manabe, Yoshihiko
AU - Yahara, Katsuya
AU - Nishikawa, Atsushi
AU - Kakuhara, Hisao
AU - Yamamoto, Kentaro
AU - Inoue, Tetsuya
AU - Takada, Yu
AU - Nagata, Kenji
AU - Suzuki, Osamu
AU - Terahara, Atsuro
AU - Jingu, Keiichi
N1 - Funding Information:
The Authors would like to thank Drs. Akira Anbai, Gencho Kuga, Hajime Ikeda, Hideya Yamazaki, Hidekazu Tanaka, Hisashi Kaizu, Hitomi Kataoka, Hiroki Kobayashi, Ichiro Ogino, Imi Takanashi, Junichi Yokouchi, Kana Kobayashi, Katsuyuki Shirai, Keisuke Fujimoto, Koda Ryuichi, Kosuke Amano, Koutaro Terashima, Masaaki Yamashina, Masayoshi Yamada, Michiko Imai, Nanae Yamaguchi, Nobuhiko Yoshikawa, Nobuhisa Mabuchi, Saeko Hirota, Miyako Myojin, Satoshi Itasaka, Seiji Kubota, Shigetoshi Shimamoto, Shinichi Ogawa, Shinya Takemoto, Syuji Otsu, Takanori Fukuda , Takashi Sakamoto, Takashi Kawanaka, Takuya Yamazaki, Shizuko Ohashi, Susumu Kanazawa, Tetsuo Nonaka, Tetsuo Saito, Toshiki Kawamura, Toshinori Soejima, Tomoyasu Kumano, Toru Sakayauchi, Tsunehiko Kan, Yasuhiro Dekura, Yo Ushijima, Yoshiaki Okamoto, Yoshisuke Matsuoka, Yuko Shirata, Yumi Sato, Yu Takada, and Yutaka Naoi for their significant support. This study was also supported by a Grant-in-Aid from the Japanese Society for Radiation Oncology 2015-2016 and by JSPS KAKENHI Grant Number JP.17K10494.
Funding Information:
The Authors would like to thank Drs. Akira Anbai, Gencho Kuga, Hajime Ikeda, Hideya Yamazaki, Hidekazu Tanaka, Hisashi Kaizu, Hitomi Kataoka, Hiroki Kobayashi, Ichiro Ogino, Imi Takanashi, Junichi Yokouchi, Kana Kobayashi, Katsuyuki Shirai, Keisuke Fujimoto, Koda Ryuichi, Kosuke Amano, Koutaro Terashima, Masaaki Yamashina, Masayoshi Yamada, Michiko Imai, Nanae Yamaguchi, Nobuhiko Yoshikawa, Nobuhisa Mabuchi, Saeko Hirota, Miyako Myojin, Satoshi Itasaka, Seiji Kubota, Shigetoshi Shimamoto, Shinichi Ogawa, Shinya Takemoto, Syuji Otsu, Takanori Fukuda, Takashi Sakamoto, Takashi Kawanaka, Takuya Yamazaki, Shizuko Ohashi, Susumu Kanazawa, Tetsuo Nonaka, Tetsuo Saito, Toshiki Kawamura, Toshinori Soejima, Tomoyasu Kumano, Toru Sakayauchi, Tsunehiko Kan, Yasuhiro Dekura, Yo Ushijima, Yoshiaki Okamoto, Yoshisuke Matsuoka, Yuko Shirata, Yumi Sato, Yu Takada, and Yutaka Naoi for their significant support. This study was also supported by a Grant-in-Aid from the Japanese Society for Radiation Oncology 2015-2016 and by JSPS KAKENHI Grant Number JP.17K10494.
Publisher Copyright:
© 2020 International Institute of Anticancer Research. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Aim: This study was performed to confirm the superior overall survival (OS) after pulmonary oligo-recurrence compared to pulmonary sync-oligometastases in a large nationwide study. Patients and Methods: Patients that met the following criteria were included: 1 to 5 lung-only metastases at the beginning of stereotactic body radiation therapy (SBRT) was performed between January 2004 and June 2015, and the biological effective dose (BED) of SBRT was 75 Gy or more. The parameters included in the analyses were age, gender, ECOG PS, primary lesion, pathology, oligoetastatic state, SBRT date, chemotherapy before SBRT, chemotherapy concurrent SBRT, chemotherapy after SBRT, maximum tumor diameter, number of metastases, field coplanarity, dose prescription, BED10, OTT of SBRT. Results: In total, 1,378 patients with 1,547 tumors were enrolled. Oligo-recurrence occurred in 1,016 patients, sync-oligometastases in 118, and unclassified oligometastases in 121. The three-year OS was 64.0% for oligo-recurrence and 47.5% for sync-oligometastasis (p<0.001). In the multivariate analysis, the hazard ratio (HR) for sync-oligometastases versus oligo-recurrence was 1.601 (p=0.014). Adverse events of Grade 5 were occurred in 3 patients. Conclusion: This is the first nationwide to indicate that the OS of patients with pulmonary oligo-recurrence is better than that of patients with sync-oligometastases.
AB - Aim: This study was performed to confirm the superior overall survival (OS) after pulmonary oligo-recurrence compared to pulmonary sync-oligometastases in a large nationwide study. Patients and Methods: Patients that met the following criteria were included: 1 to 5 lung-only metastases at the beginning of stereotactic body radiation therapy (SBRT) was performed between January 2004 and June 2015, and the biological effective dose (BED) of SBRT was 75 Gy or more. The parameters included in the analyses were age, gender, ECOG PS, primary lesion, pathology, oligoetastatic state, SBRT date, chemotherapy before SBRT, chemotherapy concurrent SBRT, chemotherapy after SBRT, maximum tumor diameter, number of metastases, field coplanarity, dose prescription, BED10, OTT of SBRT. Results: In total, 1,378 patients with 1,547 tumors were enrolled. Oligo-recurrence occurred in 1,016 patients, sync-oligometastases in 118, and unclassified oligometastases in 121. The three-year OS was 64.0% for oligo-recurrence and 47.5% for sync-oligometastasis (p<0.001). In the multivariate analysis, the hazard ratio (HR) for sync-oligometastases versus oligo-recurrence was 1.601 (p=0.014). Adverse events of Grade 5 were occurred in 3 patients. Conclusion: This is the first nationwide to indicate that the OS of patients with pulmonary oligo-recurrence is better than that of patients with sync-oligometastases.
KW - Nationwide study
KW - Pulmonary oligo-recurrence
KW - Pulmonary oligometastases
KW - Pulmonary sync-oligometastases
KW - SBRT
UR - http://www.scopus.com/inward/record.url?scp=85077382537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077382537&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13965
DO - 10.21873/anticanres.13965
M3 - Article
C2 - 31892592
AN - SCOPUS:85077382537
SN - 0250-7005
VL - 40
SP - 393
EP - 399
JO - Anticancer Research
JF - Anticancer Research
IS - 1
ER -
